Smith+Nephew reported second-quarter 2026 results on 4 August and cut its full-year revenue guidance from around 6% growth to around 4%. The disappointment sits in orthopedics: the segment declined 0.2% in the quarter, with U.S. knee implants down 7.2%. One line in the portfolio kept growing through the noise — trauma and extremities, carried by the EVOS plating system and intramedullary nails. For anyone buying fracture fixation, that contrast is the useful part of the report.
The quarter in numbers
- Q2 revenue of $1.597 billion, up 1.6% underlying and 2.8% reported with a currency tailwind.
- Full-year revenue guidance lowered to around 4% growth, from around 6%.
- First-half revenue of $3.097 billion, up 2.3% underlying; trading profit up 8.1% to $566 million.
- Orthopedics trading margin improved to 13.0%, helped by manufacturing savings.
- A $500 million share buyback is running, with $216 million settled by 3 August; the interim dividend rose 4.0%.
CEO Deepak Nath called the orthopedics performance "not where we want it to be," blaming temporary U.S. hip headwinds and a deliberate pull-back in knees ahead of the cementless LANDMARK launch later this year. The company still expects second-half growth of 5.0% to 5.5% and kept its profit, cash flow and return targets intact.
Trauma keeps growing while joints stumble
The trauma and extremities business told a different story. In the first quarter it grew 4.5% reported to $161 million, driven by the EVOS plating system and IM nail growth, and the product cadence continued into the second quarter with the launch of EVOS Pelvic, an extension of the same plating platform. The pattern matches what Stryker reported a week earlier — U.S. trauma and extremities up more than 12% — and the reason is structural. Fractures are non-elective care. A broken wrist or hip cannot be deferred the way a knee replacement can, so trauma implant demand tracks injury volumes and population aging rather than hospital capital budgets or consumer confidence. When elective joint volumes soften, plating and nailing programs keep running.
What this signals for trauma buyers
Three practical takeaways for hospitals and distributors. First, plating platforms are where the manufacturers are investing — EVOS Pelvic is the third extension of that system in two years, and platform breadth increasingly decides which systems a hospital can standardize on for tibia and fibula plating and pelvic work. Second, trauma demand is the stable line in every major manufacturer's portfolio right now, which supports firm pricing and tight allocation in nailing and hip fracture categories. Third, companies cutting revenue guidance but defending profit targets do it with manufacturing savings — buyers should expect continued footprint consolidation and occasional supply reshuffles as those programs run.
The BoneCraft angle
BoneCraft is an independent distributor of genuine orthopedic trauma implants. We track quarterly results across the big manufacturers because they tell us where platform investment and factory capacity are heading — and where lead times will tighten. When a plating line grows, stock on a distributor's shelf is the buffer that keeps a hospital supplied. Contact our team for current availability across trauma plates, nails and screws.
Sources
- Smith+Nephew Second Quarter and First Half 2026 Results — official release, 4 August 2026
- MD+DI — Smith+Nephew Cuts 2026 Outlook Amid Orthopedics Decline, 6 August 2026
- Investegate — Smith+Nephew Q1 2026 Trading Update: Trauma & Extremities +4.5% on EVOS and IM Nails
Smith+Nephew, EVOS and LANDMARK are trademarks of their respective owner. BoneCraft is an independent distributor of genuine orthopedic trauma implants and is not affiliated with, sponsored by, or endorsed by Smith+Nephew or any other manufacturer mentioned.
-
BrandName Team
Process Media Manufacturer Since 2010
pproduces tower packing, molecular sieves, ceramic grinding media and other process media from our Pingxiang production base. We supply to industrial projects in over 100 countries.
